Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to personalize pain control and avoid overmedication. Medasense’s flagship product, the PMD-200™ with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of a proprietary non-invasive sensor platform and artificial intelligence.
The PMD-200 is used to optimize pain management in critical care and operating room settings, where patients are unable to communicate.
Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid sparing, less postoperative pain experienced by patients in the post anaesthesia care unit, and reduced cost of care.
The PMD-200 is distributed in Europe exclusively by Medtronic , is cleared for marketing also in Canada, Latin America, Israel and Australia, and enables connectivity with Philips patient monitors.
Watch Medasense’s 1-minute video